This clinical trial is focused on studying a condition known as Refractory Focal Onset Epilepsy. This type of epilepsy involves seizures that start in one area of the brain and are difficult to control with standard treatments. The study will test a new medication called BHV-7000, which is taken as a prolonged-release tablet. This means the medication is designed to release slowly into the body over time. The purpose of the study is to determine if BHV-7000 is effective and safe for adults with this type of epilepsy.

Participants in the study will be randomly assigned to receive either BHV-7000 or a placebo, which looks like the medication but does not contain the active ingredient. The study will last for about eight weeks, during which participants will take the medication or placebo daily. Researchers will monitor the participants to see if there is a reduction in the number of seizures they experience. The goal is to find out if BHV-7000 can help reduce seizures by at least 50% in those taking the medication compared to those taking the placebo.

Throughout the study, the safety and tolerability of BHV-7000 will be closely observed. This means researchers will keep track of any side effects or adverse reactions participants might experience. The study aims to provide valuable information on whether BHV-7000 can be a beneficial treatment option for people with Refractory Focal Onset Epilepsy, potentially offering a new way to manage this challenging condition.